Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Infectious Diseases
Published in: BMC Infectious Diseases 1/2015

Open Access 01-12-2015 | Research article

Increasing prevalence of HIV infection among first time clients in Italian drug treatment services – is it sexual transmission?

Authors: Mario Cruciani, Lucas Wiessing, Giovanni Serpelloni, Bruno Genetti, Alessandra Andreotti, Carpignano Iulia, Monica Zermiani, Barbara Suligoi

Published in: BMC Infectious Diseases | Issue 1/2015

Login to get access

Abstract

Background

Over the last two decades, the proportion of people who inject drugs among newly reported HIV cases in Italy has been continuously declining. This trend is reflected in the prevalence of HIV infection among problem drug users followed in drug treatment services. We report nationwide trends in the prevalence of HIV and HCV among tested clients in charge to drug addiction services from 2005 to 2011.

Methods

Data on the prevalence of HIV and HCV among drug users from public drug treatment services across Italy were collected and analyzed for the period from 2005 to 2011. Prevalence of HIV and HCV were compared between clients returning to treatment and those entering treatment for the first time, and by gender. Due to the high percentage of missing data, the “inverse probability weight” method was used. Trends in testing uptake were also analysed.

Results

A significant decrease of HIV and HCV prevalence is observed among all PDUs entering treatment (from 14.7% to 11.1% and from 61.6% to 50%, respectively, in 2005–2011). By contrast, among those entering the services for the first time, after an initial decline the prevalence of HIV infection steadily increased in both sexes, from 2.2% in 2009 to 5.3% in 2011. Self-reported injecting rates in this group decreased over time, and in 2011 the proportion reporting drug injecting was lower among new clients than in people returning to services (14.5 vs. 34.4%). We also observed a progressive and significant reduction in HIV and HCV testing in drug treatment services.

Conclusions

Changes in injection practice and type of drugs used, coupled with a concurrent reduction in HCV prevalence, do not support drug injection as the main explanation for an increased HIV transmission in people entering drug treatment services for the first time. While reductions in testing rates raise concerns over data quality, the possibility of increased sexual transmission needs to be considered.
Literature
1.
Likatavicius G, van de Laar MJ. HIV infection and AIDS in the European Union and European Economic Area, 2010. Euro Surveill. 2011;16(48).
2.
Wiessing L, Likatavicius G, Hedrich D, Guarita B, van de Laar MJ, Vicente J. Trends in HIV and hepatitis C virus infections among injecting drug users in Europe, 2005 to 2010. Euro Surveill. 2011;16(48).
3.
4.
5.
MacArthur GJ, Minozzi S, Martin N, Vickerman P, Deren S, Bruneau J, et al. Opiate substitution treatment and HIV transmission in people who inject drugs: systematic review and meta-analysis. BMJ. 2012;345:e5945.CrossRefPubMedPubMedCentral
6.
7.
Wiessing L, Klempová D, Hedrich D, Montanari L, Gyarmathy VA. Injecting drug use in Europe: stable or declining. Euro Surveill. 2010;15(26).
8.
9.
Wiessing L, van de Laar MJ, Donoghoe MC, Guarita B, Klempová D, Griffiths P. HIV among injecting drug users in Europe: increasing trends in the East. Euro Surveill. 2008;13(50).
10.
Pharris A, Wiessing L, Sfetcu O, Hedrich D, Botescu A, Fotiou A, et al. Human immunodeficiency virus in injecting drug users in Europe following a reported increase of cases in Greece and Romania, 2011. Euro Surveill. 2011;16(48).
11.
12.
13.
Des Jarlais DC, Friedman SR. HIV infection among intravenous drug users: epidemiology and risk reduction. AIDS. 1987;1:67–76.PubMed
14.
Nicolosi A, Leite ML, Musicco M, Molinari S, Lazzarin A. Parenteral and sexual transmission of human immunodeficiency virus in intravenous drug users: a study of seroconversion. The Northern Italian Seronegative Drug Addicts (NISDA) Study. Am J Epidemiol. 1992;135:225–33.PubMed
15.
Kral AH, Bluthenthal RN, Lorvick J, Gee L, Bacchetti P, Edlin BR. Sexual transmission of HIV-1 among injection drug users in San Francisco, USA: risk-factor analysis. Lancet. 2001;357(9266):1397–401.CrossRefPubMed
16.
Strathdee SA, Galai N, Safaiean M, Celentano DD, Vlahov D, Johnson L, et al. Sex differences in risk factors for hiv seroconversion among injection drug users: a 10-year perspective. Arch Intern Med. 2001;161:1281–8.CrossRefPubMed
17.
Des Jarlais C, Semaan S. HIV and other sexually transmitted infections in injection drug users and crack cocaine smokers. In: Holmes K, Sparling P, Stamm W, et al., editors. Sexually transmitted diseases. 4th ed. New York: McGraw Hill; 2008. p. 237–55.
18.
Urbina A, Jones K. Crystal methamphetamine, its analogues, and HIV infection: medical and psychiatric aspects of a new epidemic. Clin Infect Dis. 2004;38:890–4.CrossRefPubMed
19.
Colfax GN, Mansergh G, Guzman R, Vittinghoff E, Marks G, Rader M, et al. Drug use and sexual risk behavior among gay and bisexual men who attend circuit parties: A venue-based comparison. JAIDS. 2001;28:373–9.PubMed
20.
21.
Daskalopoulou M, Phillips A, Sherr L, Rodger A, Speakman A, Edwards S, et al. Recreational drug use and high risk sexual behaviour among HIV-diagnosed men who have sex with men (MSM) in the UK: results from the Antiretrovirals, Sexual Transmission Risk and Attitudes (ASTRA) study. 14th EACS, 16-19 October 2013, Brussels Oral abstract PS 11.3.
22.
Camoni L, Regine V, Salfa MC, Nicoletti G, Canuzzi P, Magliocchetti N, et al. Continued high prevalence of HIV, HBV and HCV among injecting and noninjecting drug users in Italy. Ann Ist Super Sanità. 2010;46:59–65.CrossRefPubMed
23.
Neaigus A, Gyarmathy VA, Miller M, Fiedman SR, Des Jarlais DC. Sexual and other noninjection risks for HBV and HCV seroconversions among non injecting heroin users. J Infect Dis. 2007;195:1052–61.CrossRefPubMed
24.
Des Jarlais DC, Arasteh K, Perlis T, Hagan H, Heckathorn DD, Mcknight C, et al. The transition from injection to non-injection drug use: long term outcomes among heroin and cocaine users in New York City. Addiction. 2007;102:778–85.CrossRefPubMed
25.
Lindenburg CE, Krol A, Smit C, Buster MC, Coutinho RA, Prins M. Decline in HIV incidence and injecting, but not in sexual risk behaviour, seen in drug users in Amsterdam: a 19-year prospective cohort study. AIDS. 2006;20:1771–5.CrossRefPubMed
26.
Seaman SR, White IR. Review of inverse probability weighting for dealing with missing data. Stat Methods Med Res. 2013;22:278–95.CrossRefPubMed
27.
28.
Vickerman P, Martin NK, Roy A, Beattie T, EMCDDA Collaborative Group, Jarlais DD, et al. Is the HCV-HIV co-infection prevalence amongst injecting drug users a marker for the level of sexual and injection related HIV transmission? Drug Alcohol Depend. 2013;132:172–81.CrossRefPubMed
29.
Vickerman P, Hickman M, May M, Kretzschmar M, Wiessing L. Can hepatitis C virus prevalence be used as a measure of injection-related human immunodeficiency virus risk in populations of injecting drug users? An ecological analysis. Addiction. 2010;105:311–8.CrossRefPubMed
30.
de Vos AS, van der Helm JJ, Prins M, Kretzschmar ME. Determinants of persistent spread of HIV in HCV-infected populations of injecting drug users. Epidemics. 2012;4:57–67.CrossRefPubMed
31.
Kraus L, Augustin R, Frischer M, Kümmler P, Uhl A, Wiessing L. Estimating prevalence of problem drug use at national level in countries of the European Union and Norway. Addiction. 2003;98:471–85.CrossRefPubMed
32.
Camoni L, Federico B, Capelli G, Salfa MC, Regine V, Nicoletti G, et al. [Proportion of drug users in treatment who have never undergone serological testing for HIV, HBV and HCV and correlates of failure to undergo testing: Italy, 2005-2007]. Ann Ig. 2009;21:315.PubMed
33.
Camoni L, Federico B, Capelli G, Regine V, Salfa MC, Nicoletti G, et al. Few Italian Drug Users Undergo HIV Testing. AIDS Behav. 2011;15:711–7.CrossRefPubMed
34.
Gowing L, Farrell MF, Bornemann R, Sullivan LE, Ali R. Oral substitution treatment of injecting opioid users for prevention of HIV infection. Cochrane Database Syst Rev. 2011;8:CD004145.PubMed
35.
Mathers BM, Degenhardt L, Ali H, Wiessing L, Hickman M, Mattick RP, et al. 2009 Reference Group to the UN on HIV and Injecting Drug Use. HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage. Lancet. 2010;375(9719):1014–28.CrossRefPubMed
36.
Seidenberg A, Rosemann T, Senn O. Patients receiving opioid maintenance treatment in primary care: successful chronic hepatitis C care in a real world setting. BMC Infect Dis. 2013;13:9.CrossRefPubMedPubMedCentral
37.
38.
Marks G, Crepaz N, Janssen RS. Estimating sexual transmission of HIV from persons aware and unaware that they are infected with the virus in the USA. AIDS. 2006;20:1447–50.CrossRefPubMed
39.
Mocroft A, Lundgren JD, Sabin ML, Monforte AD, Brockmeyer N, Casabona J, et al. Risk factors and outcomes for late presentation for HIV-positive persons in Europe: results from the collaboration of observational HIV epidemiological research europe study (COHERE). PLoS Med. 2013;10(9):e1001510.CrossRefPubMedPubMedCentral
40.
Smit C, van den Berg C, Geskus R, Berkhout B, Coutinho R, Prins M. Risk of hepatitis-related mortality increased among hepatitis C virus/HIV-coinfected drug users compared with drug users infected only with hepatitis C virus: a 20-year prospective study. J Acquir Immune Defic Syndr. 2008;47:221–5.CrossRefPubMed
41.
Zucchetto A, Bruzzone S, De Paoli A, Regine V, Pappagallo M, Dal Maso L, et al. AIDS and injecting drug use: survival determinants in the highly active antiretroviral therapy era. Epidemiol Prev. 2009;33:184–9.PubMed
42.
Metadata
Title
Increasing prevalence of HIV infection among first time clients in Italian drug treatment services – is it sexual transmission?
Authors
Mario Cruciani
Lucas Wiessing
Giovanni Serpelloni
Bruno Genetti
Alessandra Andreotti
Carpignano Iulia
Monica Zermiani
Barbara Suligoi
Publication date
01-12-2015
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2015
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-015-0940-x

Other articles of this Issue 1/2015

BMC Infectious Diseases 1/2015 Go to the issue

Research article

Shiga toxin-producing escherichia coli infections in Norway, 1992–2012: characterization of isolates and identification of risk factors for haemolytic uremic syndrome

Research article

Changing risk awareness and personal protection measures for low to high pathogenic avian influenza in live-poultry markets in Taiwan, 2007 to 2012

Case report

Recurrent severe invasive pneumococcal disease in an adult with previously unknown hyposplenia

Research article

Higher blood volumes improve the sensitivity of direct PCR diagnosis of blood stream tuberculosis among HIV-positive patients: an observation study

Review

Current and future antimicrobial treatment of gonorrhoea – the rapidly evolving Neisseria gonorrhoeae continues to challenge

Case report

Periodontitis-associated septic pulmonary embolism caused by Actinomyces species identified by anaerobic culture of bronchoalveolar lavage fluid: a case report
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits